Clinical Trials Directory

Trials / Completed

CompletedNCT03422536

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
78 (actual)
Sponsor
University of Arizona · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This randomized phase II trial studies how well ficlatuzumab with or without cetuximab works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other places in the body and resistant to cetuximab treatment. Monoclonal antibodies, such as ficlatuzumab and cetuximab, may block growth signals that lets a tumor cell survive and reproduce, and helps the immune system recognize and fight head and neck squamous cell carcinoma.

Detailed description

PRIMARY OBJECTIVES: I. To assess the efficacy of ficlatuzumab, with or without concurrent cetuximab, in patients with cetuximab-resistant, recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) as measured by progression-free survival (PFS). SECONDARY OBJECTIVES: I. To describe toxicity. II. To evaluate response rate and overall survival in both treatment arms. EXPLORATORY OBJECTIVES I. To describe patient reported quality of life II. To evaluate the relationship between clinical outcomes (Progression-Free Survival and Response Rate) and candidate tumoral, genomic, peripheral, and immune biomarkers, potentially including but not limited to: * Tumor Hepatocyte Growth Factor (HGF) and tyrosine-protein kinase Met (cMet) expression * mutations in PIK3CA, phosphatase and tensin homolog (PTEN), and HumanRAS proto-oncogene (HRAS); * peripheral serum biomarkers including HGF, soluble HGF, and interleukin 6 (IL6); * peripheral lymphocyte populations; * archived and baseline immune infiltrate; * tumor Human Papilloma Virus (HPV) status. OUTLINE: Patients are randomized into 1 of 2 arms. Arm I: Patients receive ficlatuzumab intravenously (IV) over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Arm II: Patients receive cetuximab IV over 60 -120 minutes and ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years.

Conditions

Interventions

TypeNameDescription
BIOLOGICALCetuximabGiven IV
DRUGFiclatuzumabGiven IV

Timeline

Start date
2017-12-05
Primary completion
2022-03-29
Completion
2022-04-05
First posted
2018-02-05
Last updated
2024-09-04
Results posted
2023-07-19

Locations

6 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03422536. Inclusion in this directory is not an endorsement.